Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes : A single-centre randomized controlled study

Show simple item record

dc.contributor.author Matikainen, Niina
dc.contributor.author Söderlund, Sanni
dc.contributor.author Björnson, Elias
dc.contributor.author Pietiläinen, Kirsi
dc.contributor.author Hakkarainen, Antti
dc.contributor.author Lundbom, Nina
dc.contributor.author Taskinen, Marja-Riitta
dc.contributor.author Boren, Jan
dc.date.accessioned 2019-12-31T22:55:00Z
dc.date.available 2021-12-17T22:02:48Z
dc.date.issued 2019-01
dc.identifier.citation Matikainen , N , Söderlund , S , Björnson , E , Pietiläinen , K , Hakkarainen , A , Lundbom , N , Taskinen , M-R & Boren , J 2019 , ' Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes : A single-centre randomized controlled study ' , Diabetes, obesity and metabolism , vol. 21 , no. 1 , pp. 84-94 . https://doi.org/10.1111/dom.13487
dc.identifier.other PURE: 120623203
dc.identifier.other PURE UUID: 475cea15-d36f-4875-b26b-ac6282379c77
dc.identifier.other WOS: 000452202600009
dc.identifier.other Scopus: 85052932195
dc.identifier.other ORCID: /0000-0002-6229-3588/work/90756860
dc.identifier.other ORCID: /0000-0003-0041-1240/work/94378143
dc.identifier.uri http://hdl.handle.net/10138/308850
dc.description.abstract Aims Patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) exhibit considerable residual risk for cardiovascular disease (CVD). There is, therefore, increasing interest in targeting postprandial lipid metabolism and remnant cholesterol. Treatment with the glucagon-like peptide 1 (GLP-1) analogue liraglutide reduces CVD risk by mechanisms that remain unexplained in part. Here we investigated the effects of liraglutide intervention on ectopic fat depots, hepatic lipogenesis and fat oxidation, postprandial lipid metabolism and glycaemia in humans with type 2 diabetes. Methods The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes. Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks. Because liraglutide is known to promote weight loss, the study included dietary counselling to achieve similar weight loss in the liraglutide and placebo groups. Cardiometabolic responses to a high-fat mixed meal were measured before and at the end of the liraglutide intervention. Results Weight loss at Week 16 was similar between the groups: -2.4 kg (-2.5%) in the liraglutide group and -2.1 kg (-2.2%) in the placebo group. HBA1c improved by 6.4 mmol/mol (0.6%) in the liraglutide group (P = 0.005). Liver fat decreased in both groups, by 31% in the liraglutide group and by 18% in the placebo group, but there were no significant changes in the rate of hepatic de novo lipogenesis or beta-hydroxybutyrate levels, a marker of fat oxidation. We observed significant postprandial decreases in triglycerides only in plasma, chylomicrons and VLDL, and remnant particle cholesterol after treatment in the liraglutide group. Fasting and postprandial apoCIII concentrations decreased after liraglutide intervention and these changes were closely related to reduced glycaemia. In relative importance analysis, approximately half of the changes in postprandial lipids were explained by reductions in apoCIII concentrations, whereas less than 10% of the variation in postprandial lipids was explained by reductions in weight, glycaemic control, liver fat or postprandial insulin responses. Conclusions Intervention with liraglutide for 16 weeks produces multiple improvements in cardiometabolic risk factors that were not seen in the placebo group, despite similar weight loss. Of particular importance was a marked reduction in postprandial atherogenic remnant particles. The underlying mechanism may be improved glycaemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients. en
dc.format.extent 11
dc.language.iso eng
dc.relation.ispartof Diabetes, obesity and metabolism
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject apolipoprotein C3
dc.subject atherogenic dyslipidaemia
dc.subject de novo lipogenesis
dc.subject GLP-1-agonist
dc.subject liraglutide
dc.subject liver fat
dc.subject postprandial lipids
dc.subject remnant lipoproteins
dc.subject FATTY LIVER-DISEASE
dc.subject REMNANT CHOLESTEROL
dc.subject VILDAGLIPTIN THERAPY
dc.subject RECEPTOR AGONISTS
dc.subject TRIGLYCERIDE
dc.subject LIPOPROTEINS
dc.subject METFORMIN
dc.subject EXENATIDE
dc.subject PARTICLES
dc.subject PLACEBO
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes : A single-centre randomized controlled study en
dc.type Article
dc.contributor.organization Clinicum
dc.contributor.organization Diabetes and Obesity Research Program
dc.contributor.organization Research Programs Unit
dc.contributor.organization Department of Medicine
dc.contributor.organization Endokrinologian yksikkö
dc.contributor.organization University of Helsinki
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization Faculty of Medicine
dc.contributor.organization HUS Internal Medicine and Rehabilitation
dc.contributor.organization Department of Diagnostics and Therapeutics
dc.contributor.organization HUS Medical Imaging Center
dc.contributor.organization Marja-Riitta Taskinen Research Group
dc.contributor.organization HUS Heart and Lung Center
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1111/dom.13487
dc.relation.issn 1462-8902
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Matikainen_et_a ... Obesity_and_Metabolism.pdf 1.157Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record